CBU
CTKB icon

CIBC Bancorp USA’s Cytek Biosciences CTKB Stock Holding History

CIBC Bancorp USA’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$43.5K Buy
+12,533
New +$47K ﹤0.01% 1426

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Bancorp USA's CTKB Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Cytek Biosciences (CTKB) in Q3 2025: 12,533 shares worth $43.5K. The stake represents ﹤0.01% of the portfolio and ranks #1426 among its holdings.

153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • CIBC Bancorp USA held 12,533 shares of Cytek Biosciences worth $43.5K as of Q3 2025.
  • Cytek Biosciences was a new CIBC Bancorp USA position in Q3 2025.
  • Cytek Biosciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1426 holding.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.